Lista de obras -

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma

artículo científico publicado en 2009

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2013

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning

artículo científico publicado en 2017

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning

artículo científico publicado en 2010

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens

artículo científico publicado en 2004

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

artículo científico publicado en 2002

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

artículo científico publicado en 2019

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

artículo científico publicado en 2018

Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach

artículo científico publicado en 2016

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

artículo científico publicado en 2015

Clinical and Neuroimaging Correlates of Post-Transplant Delirium

scientific article published on 19 September 2020

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics

artículo científico publicado en 2014

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

artículo científico publicado en 2016

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

artículo científico publicado en 2014

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors

artículo científico publicado en 2011

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

artículo científico publicado en 2020

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

artículo científico publicado en 2017

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

artículo científico publicado en 2017

Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors ⬇️

artículo científico publicado el 1 de enero de 2011

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

artículo científico publicado en 2017

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics

artículo científico publicado en 2007

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma

artículo científico publicado en 2009

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

artículo científico publicado en 2018

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

artículo científico publicado en 2017

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation

artículo científico publicado en 2012

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

artículo científico publicado en 2018

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

artículo científico publicado en 2020

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

artículo científico publicado en 2010

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

scientific article published on 20 October 2020

Lenalidomide-Associated ITP.

artículo científico publicado en 2011

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

scientific article published on 01 June 2004

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry

artículo científico publicado en 2012

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF

scientific article published on 01 April 2002

Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment

artículo científico publicado en 2006

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology

artículo científico publicado en 2015

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Multiple myeloma

scientific article published on 01 October 2011

Multiple myeloma, version 1.2013.

artículo científico publicado en 2013

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients

artículo científico publicado en 2008

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

artículo científico publicado en 2016

NCCN clinical practice guidelines in oncology: multiple myeloma

artículo científico publicado en 2009

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation

artículo científico publicado en 2010

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells

scientific article published on 01 January 2002

Older patients with myeloma derive similar benefit from autologous transplantation.

artículo científico publicado en 2014

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

artículo científico publicado en 2016

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation

artículo científico publicado en 2011

Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.

artículo científico publicado en 2007

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

artículo científico publicado en 2013

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade

scientific article published on 09 October 2018

Panobinostat for the management of multiple myeloma

artículo científico publicado en 2016

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

artículo científico publicado en 2007

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

artículo científico publicado en 2018

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

artículo científico publicado en 2004

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

artículo científico publicado en 2016

Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation

artículo científico publicado en 2020

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

artículo científico publicado en 2017

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

artículo científico publicado en 2016

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

artículo científico publicado en 2016

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation

artículo científico publicado en 2004

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment

artículo científico publicado en 2013

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality

scientific article published on 11 September 2020

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

artículo científico publicado en 2011

Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study

artículo científico publicado en 2014

Recognition of early mortality in multiple myeloma by a prediction matrix

artículo científico publicado en 2017

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

artículo científico publicado en 2013

Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial ⬇️

artículo científico publicado el 26 de agosto de 2010

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors

artículo científico publicado en 2008

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma

scientific article published on 21 December 2018

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

scholarly article by Nizar J Bahlis et al published 23 October 2018 in Blood

Stem cell transplantation for multiple myeloma

artículo científico publicado en 2004

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen

artículo científico publicado en 2001

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

artículo científico publicado en 2020

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

artículo científico publicado en 2018

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization

artículo científico publicado en 2017

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

artículo científico publicado en 2014

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial

artículo científico publicado en 2016

Unrelated umbilical cord blood transplantation in adult patients

artículo científico publicado en 2003

Use of Cyclosporine Is Associated with the Increase in Pre-Engraftment Syndrome After Myeloablative Dual Cord Blood Transplantation

scholarly article by J. Kanda et al published February 2012 in Biology of Blood and Marrow Transplantation

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

artículo científico publicado en 2020

Lista de obras de

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Clinical and Neuroimaging Correlates of Post-Transplant Delirium

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors ⬇️

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Lenalidomide-Associated ITP.

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF

Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Multiple myeloma

Multiple myeloma, version 1.2013.

Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

NCCN clinical practice guidelines in oncology: multiple myeloma

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells

Older patients with myeloma derive similar benefit from autologous transplantation.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation

Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade

Panobinostat for the management of multiple myeloma

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration

Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study

Recognition of early mortality in multiple myeloma by a prediction matrix

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial ⬇️

Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Stem cell transplantation for multiple myeloma

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation.

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial

Unrelated umbilical cord blood transplantation in adult patients